Q1 2019 13F Holders as of 3/31/2019
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
126M
-
Number of holders
-
100
-
Total 13F shares, excl. options
-
51.1M
-
Shares change
-
+3.76M
-
Total reported value, excl. options
-
$298M
-
Value change
-
+$12.3M
-
Put/Call ratio
-
0.51
-
Number of buys
-
56
-
Number of sells
-
-46
-
Price
-
$5.84
Significant Holders of Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) as of Q1 2019
134 filings reported holding KPTI - Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share as of Q1 2019.
Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) has 100 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 51.1M shares
of 126M outstanding shares and own 40.38% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (8.44M shares), Palo Alto Investors LP (5.26M shares), Consonance Capital Management LP (5.16M shares), BlackRock Inc. (4.18M shares), MILLENNIUM MANAGEMENT LLC (2.72M shares), VANGUARD GROUP INC (2.61M shares), Candriam Luxembourg S.C.A. (1.87M shares), CITADEL ADVISORS LLC (1.79M shares), FMR LLC (1.53M shares), and EMERALD ADVISERS, LLC (1.51M shares).
This table shows the top 100 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.